HPV vaccine and screening brought to women who need it most
NCT ID NCT06414057
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to make cervical cancer prevention easier for women who often miss out on routine care, such as those experiencing homelessness, substance use, or incarceration. Researchers will offer the HPV vaccine (Gardasil-9) and a self-swab test during regular sexual health clinic visits. They will track how many women accept the offer and complete the vaccine series, and gather feedback to design better services.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gardasil-9 (HPV vaccine)
What this could lead to
If successful, this could show that offering HPV vaccines during routine sexual health visits is a practical way to reach and protect women who often miss standard screening and vaccination.
What could go wrong
This is a small, early feasibility study (500 participants) focused on uptake and attitudes, not on directly preventing cancer. Results may not apply to other regions or populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NHS Lothian
RECRUITINGEdinburgh, United Kingdom
Contact